There are currently 1887 clinical trials in Los Angeles, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Cedars-Sinai Medical Center, USC / Norris Comprehensive Cancer Center, Childrens Hospitla Los Angeles and University of California Los Angeles. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
NCT06697197
Recruiting
The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Local Institution - 0030, Los Angeles, California
Conditions: Advanced Solid Tumors
Register for Updates
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332
Recruiting
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: UCLA Medical Center, Los Angeles, California +1 locations
Conditions: Metastatic Uveal Melanoma
Register for Updates
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
NCT05949684
Recruiting
The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: UCLA Hematology/Oncology - Westwood (Building 200 Suite 120), Los Angeles, California
Conditions: Myelodysplastic Syndromes
Register for Updates
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07090330
Recruiting
This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Oruka Therapeutics Investigative Site, Los Angeles, California
Conditions: Plaque Psoriasis
Register for Updates
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
NCT06874621
Recruiting
This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease. This study will look at how safe the drug is and how it works in the brain. It was first tested in normal, healthy participants who volunteered to participate. The study will look at three different dose levels, starting with the lowest dose first and moving to higher doses and more participants after safety has been reviewed by doctors an... Read More
Gender:
ALL
Ages:
Between 50 years and 90 years
Trial Updated:
08/18/2025
Locations: VYGR Site 840018, Los Angeles, California
Conditions: Alzheimer's Disease (AD)
Register for Updates
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
NCT06188208
Recruiting
A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: California Research Institute, Los Angeles, California
Conditions: Advanced Solid Tumors, Advanced Hematologic Tumors
Register for Updates
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563
Recruiting
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: University of Southern California, Los Angeles, California
Conditions: Glioblastoma
Register for Updates
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326
Recruiting
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California +1 locations
Conditions: Adenocarcinoma, Pancreatic Ductal
Register for Updates
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/18/2025
Locations: Akero Clinical Study Site, Los Angeles, California +1 locations
Conditions: NASH With Fibrosis, MASH With Fibrosis
Register for Updates
DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes
NCT06445946
Recruiting
This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational diabetes mellitus (GDM) randomized to oral metformin versus injectable insulin. This study will determine if metformin is not inferior to insulin in reducing adverse pregnancy outcomes, is comparably safe for exposed individuals and children, and if patient-reported factor... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Cedars Sinai Medical Center, Los Angeles, California
Conditions: Gestational Diabetes Mellitus, Pregnancy, High Risk
Register for Updates
Strategy for Improving Stroke Treatment Response
NCT05948566
Recruiting
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Kaiser Permanente Los Angeles, Los Angeles, California
Conditions: Ischemic Stroke
Register for Updates
Blue Light Cystoscopy With Cysview® Registry
NCT02660645
Recruiting
Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: USC/Norris Comprehensive Cancer Center, Los Angeles, California +1 locations
Conditions: Bladder Cancer
Register for Updates